Alterations in steroid hormone receptors in the tamoxifentreated endometrium

American Journal of Obstetrics and Gynecology

Volumn 176, Issue 1 I, 1997, Pages 129-137

  Schwartz, Lisa Barrie ^a,b,c   Krey, Lewis ^a,b   Demopoulos, Rita ^a,c   Goldstein, Steven R ^b,c   Nachtigall, Lua E ^a,b,c   Mittal, Khush ^a,b,c  

^a New York University School of Medicine ^*

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Endometrial polyps; Estrogen receptors; Menopause; Progesterone receptors; Tamoxifen

Indexed keywords

ANTIESTROGEN; STEROID RECEPTOR; TAMOXIFEN;

AGED; ARTICLE; BIOSYNTHESIS; DRUG EFFECT; ENDOMETRIUM; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

AGED; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0030641037     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(97)80025-7     Document Type: Article

References (25)

1. Early Breast Cancer Trials Collaborative Group. Effects of tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
2. Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996;65:1083-9.
3. Forlander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:1-17-20.
4. Rutqvist LE, Cedermark B, Glas U. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res Treat 1987;10:255-66.
5. Anzai Y, Holinka CF, Kuramoto H, Gurpide E. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 1989;49:2362-5.
6. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48: 812-5.
7. Mittal KR, Demopoulos RI, Goswami S. Proliferating clee nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. AmJ Surg Pathol 1993; 17: 117-22.
8. Gold LI, Saxena B, Mittal KR, Goswami S, Nachtigall L, Köre M, et al. Increased expression of transforming growth factor B isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 1994;54:2347-58.
9. Noyes RW, Hertig DT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1:3-25.
10. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 1988;67:334-40.
11. Snijders MPML, de Goeij AFPM, Debets-Te Baerts MJC, Rousch MJM, Koudstaal J, Bosman FT. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil 1992;94:363-71.
12. De Cecco L, Leone M, Gerbaldo D, Venturini PL, Rissone R, Messeni, et al. Steroid therapy and the endometrium: biological and clinical implications. Ann N Y Acad Sci 1991;622:296-301.
13. Satyaswaroop PG, Zaino RYJ, Mörtel R. Estrogen-like effects of tamoxif'en in human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-10.
14. Ismail SM. Pathology of endometrium treated with tainoxifen.J Clin Pathol 1994:47:827-33.
15. Jamil A, CroxtallJD, White JO. The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J Mol Endocrinol 1991:6:215-21.
16. Vering A, Vockel A, Stegmuller M, Bender HG. Immunobiochemical assay for determination of nuclear steroid receptors during tamoxifen therapy. J Cancer Res Clin Oncol 1993:119:415-20.
17. Schwanz PF., MacLusky N, Naftolin F, Eiscnfeld A. Tamoxifen-induced increase in cytosol progesterone receptor levels in a case of metastatic endometrial cancer. Gynecol Oncol 1983:16:41-8.
18. Perez-Lopez FR, Blasco Comenge J. Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Gvnecol Endocrinol 1993:7:185-9.
19. Incc BA, Schodin DJ, Shapiro DJ, Katenellenbogen BS. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. Endocrinology 1995:136:3194-9.
20. Webb P, Lopez GN, Uht RM. Kushner PJ. Tamoxifeii activation of the estrogen receptor AP-1 pathway: potential origin of the cell-specific estrogen-likc effects of antiestrogens. Mol Endocrinol 1995;9:443-5B.
21. DeMuylcler X, Ncven P, Sesoiner M, van Belle Y, Vanderick G., DeMnylder E. Endometrial lesions in patients undergoing tamoxifen therapy. IntJ Gynecol Obstet 1991;36:127-30.
22. Corley D, Rowe J, (Amis MT, Hogan M, Noumoff JS, I.ivolsi VA. Postnienopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gvnecol 1992;79:111-6.
23. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-22.
24. Gill PG, Gebski V, Snyder R, Burns 1, I.evi J, Bvrne M, et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment responses and survival in patients with metastatk breast cancer. Ann Oncol 1993;4:741-4.
25. Satyaswaroop PG, C'.larke CL, Zaino RJ, Mortel R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitiation following downrcgulation of tumor progesterone receptor. Cancer Lett 1992:62:107-14.